Targeting ID to Inhibit the Vascularization of Breast Tumors

Abstract

Under the auspices of this Army Concept Award we have begun the derivatization of a compound (AIL, for anti-Id lead) shown to bind to the Id proteins, known to be required for the formation of blood vessels into breast tumors. We have identified sites on AIL that can be modified and have begun the chemistry of adding a linker to this region of the molecule that can accept geldanamycin. The AIL-geldanamycin fusion will be used to target the Id proteins for degradation in human cancers and thereby inhibit tumor angiogenesis.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2001
Accession Number
ADB275101

Entities

People

  • Robert Benezra

Organizations

  • Memorial Sloan Kettering Cancer Center

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Blood
  • Blood Vessels
  • Breast Cancer
  • Cancer
  • Chemistry
  • Computer Programs
  • Contractors
  • Diseases And Disorders
  • Government (Foreign)
  • Government Procurement
  • Governments
  • Lead Compounds
  • Neoplasms
  • New York
  • Targeting

Fields of Study

  • Chemistry

Readers

  • Molecular Genetics
  • Oncology (Cancer Research).
  • Sensor Fusion and Tracking Systems.